Fully Synthetic TF-Based Self-Adjuvanting Vaccine Simultaneously Triggers iNKT Cells and Mincle and Protects Mice against Tumor Development
Journal of Medicinal Chemistry · 10.10.2024 · 67 (19) · 17640-17656
DOI: 10.1021/acs.jmedchem.4c01631 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 20.09.2024. Verfasst von Deying Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, International …. Hauptthemen laut MEDLINE: Cancer Vaccines, Lectins, C-Type, Natural Killer T-Cells. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Guangdong Provincial Department of Science and Technology, Basic and Applied Basic Research Foundation of Guangdong Province, Guangdong Provincial Pearl River Talents Program.
Abstract (Originalsprache)
The Thomsen-Friedenreich (TF) antigen has proven to be a promising target for developing novel therapeutic cancer vaccines. Here, a new strategy that TF antigen covalently coupled with KRN7000 and vizantin was developed. The resulting three-component vaccine KRN7000-TF-vizantin simultaneously triggers invariant natural killer T (iNKT) cells and macrophage-inducible C-type lectin (Mincle) signaling pathways, eliciting much stronger TF-specific immune responses than glycoprotein vaccine TF-KLH/alum and the corresponding two-component conjugate vaccines TF-KRN7000 and TF-vizantin. The analysis of IgG isotypes and the secretion of cytokines revealed that KRN7000-TF-vizantin induced Th1/Th2 mixed immune responses, where Th1 was dominant. In vivo experiments demonstrated that KRN7000-TF-vizantin increased the survival rate and survival time of tumor-challenged mice, and surviving mice rejected further tumor attacks without any additional treatment. This work demonstrates that covalently coupled KRN7000 and vizantin could serve as a promising TF-based vaccine carrier for antitumor immune therapy, and KRN7000-TF-vizantin features great potential to be a vaccine candidate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People's Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of…
- Affiliated Hospital of Guangdong Medical University, Zhanjiang 524001, China.
- Guangzhou Yuemei Pharmaceutical Technology Co., Ltd., Guangzhou 510535, China.
ORCID-Profile: Xiang Luo, Zhongqiu Liu, Guochao Liao
Förderung
- Guangdong Provincial Department of Science and Technology
- Basic and Applied Basic Research Foundation of Guangdong Province
- Guangdong Provincial Pearl River Talents Program
- Guangzhou Municipal Science and Technology Program key projects
- Guangdong Special Support Plan
- National Natural Science Foundation of China
- Basic and Applied Research Project of Guangzhou
- Key Laboratory of Guangdong Provincial Food and Drug Administration
Zitieren
APA
Yang, D., Li, X., Li, J., Liu, Z., Li, T., Liao, P., Luo, X., Liu, Z., Ming, W., & Liao, G. (2024). Fully Synthetic TF-Based Self-Adjuvanting Vaccine Simultaneously Triggers iNKT Cells and Mincle and Protects Mice against Tumor Development. Journal of Medicinal Chemistry, 67(19), 17640-17656. https://doi.org/10.1021/acs.jmedchem.4c01631
Vancouver
Yang D, Li X, Li J, Liu Z, Li T, Liao P, et al. Fully Synthetic TF-Based Self-Adjuvanting Vaccine Simultaneously Triggers iNKT Cells and Mincle and Protects Mice against Tumor Development. Journal of Medicinal Chemistry. 2024;67(19):17640-17656. doi:10.1021/acs.jmedchem.4c01631
BibTeX
@article{Yang2024,
author = {Yang, Deying and Li, Xiaohui and Li, Jinmei and Liu, Zichun and Li, Tongtong and Liao, Pan and Luo, Xiang and Liu, Zhongqiu and Ming, Wenbo and Liao, Guochao},
title = {Fully Synthetic TF-Based Self-Adjuvanting Vaccine Simultaneously Triggers iNKT Cells and Mincle and Protects Mice against Tumor Development},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {19},
pages = {17640--17656},
doi = {10.1021/acs.jmedchem.4c01631}
}
EUVIMED